Advocacy/Health Policy
APHON is committed to ensuring that pediatric hematology/oncology nurses are provided with the latest information on pending legislative and regulatory issues and activities impacting the profession and patients. For more information, view our health policy agenda or contact us at This email address is being protected from spambots. You need JavaScript enabled to view it..
Legislative Action Center
The APHON Legislative Action Center provides federal and state legislative information about pediatric hematology/oncology patient care and nursing. Get involved by staying informed and taking action!
Access the APHON Legislative Action Center
Advocacy Correspondent
A quarterly offering from the Association of Pediatric Hematology/Oncology Nurses, the newsletter's goal is to inform members about legislative and regulatory issues impacting the profession of pediatric hematology/oncology nursing and the patients we serve.
Access the Advocacy Correspondent
Sign-On Letters
Sign-on letters are policy-oriented letters sent to Congress members, congressional committees, or federal agencies expressing the signatories' viewpoint.
View 2023 Sign-On Letters
APHON Letter to FDA Regarding Partial Clinical Hold for ALL Trials
March 1, 2023
APHON sent a letter to the FDA to express our concerns regarding the partial clinical hold for certain Children’s Oncology Group clinical trials. APHON can provide a unique perspective on this issue as our membership has first hand knowledge of the importance of pediatric clinical trials.
Letter to House and Senate Committee Leadership Supporting the Need for Pediatric Reference Intervals
February 22, 2023
APHON joined 32 other organizations to support the need for pediatric reference intervals to ensure appropriate care for children.
Letter to Senate Health, Education, Labor, and Pension Committee Leadership on PCHETA
February 16, 2023
APHON joined the Patient Quality of Life Coalition (PQLC) in thanking the Senate Health, Education, Labor, and Pension (HELP) Committee for holding a hearing, “Examining Health Care Workforce Shortages: Where Do We Go From Here?”and their work on this important issue. The letter also requests their consideration of the Palliative Care and Hospice Education and Training Act (PCHETA) which would address interdisciplinary workforce shortages for the care of patients with serious illness.
Letter to the US Food and Drug Administration (FDA) Expressing Concern of a Partial Clinical Hold for Trials AALL1731 and AALL1821, Both of Which Include the Delivery of Blinatumomab.
February 13, 2023
APHON joined the Alliance for Childhood Cancer to let the FDA know of our concerns regarding the clinical hold for two clinical trials the Children’s Oncology Group (COG) is conducting for standard risk and relapsed acute lymphoblastic leukemia (ALL). The FDA has disallowed the delivery of 72- and 96-hour IV bags of blinatumomab to newly diagnosed patients enrolling in AALL1731 and AALL1821 due to safety concerns.
Letter to All Senate and House Members Welcoming them to the 118th Congress
January 11, 2023
APHON joined the Nursing Community Coalition (NCC) to welcome all members of the Senate and House to the 118th Congress and outlined our shared priorities of investing in the Title VIII Nursing Workforce Development programs and supporting nursing research.
Access Archived Sign-On Letters
Coalitions
Many times, the best way to make an impact with a broad audience is to partner with a coalition that can help advance our priority issues. APHON belongs to the following coalitions:
APHON is also an active member of the Nursing Community Coalition which is comprised of 63 national professional nursing associations.